These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35795152)

  • 1. Impact of Obesity on Vaccination to SARS-CoV-2.
    Nasr MC; Geerling E; Pinto AK
    Front Endocrinol (Lausanne); 2022; 13():898810. PubMed ID: 35795152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
    Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
    Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
    Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
    Front Immunol; 2022; 13():917905. PubMed ID: 35799790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body fat percentage is independently and inversely associated with serum antibody responses to SARS-CoV-2 mRNA vaccines.
    Ducharme JB; McKenna ZJ; Fennel ZJ; Nava RC; Mermier CM; Deyhle MR
    Sci Rep; 2022 Nov; 12(1):19224. PubMed ID: 36357408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine.
    Yamamoto S; Mizoue T; Tanaka A; Oshiro Y; Inamura N; Konishi M; Ozeki M; Miyo K; Sugiura W; Sugiyama H; Ohmagari N
    Obesity (Silver Spring); 2022 May; 30(5):999-1003. PubMed ID: 35226399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough SARS-CoV-2 infections after vaccination: a critical review.
    Mohseni Afshar Z; Barary M; Hosseinzadeh R; Alijanpour A; Hosseinzadeh D; Ebrahimpour S; Nazary K; Sio TT; Sullman MJM; Carson-Chahhoud K; Babazadeh A
    Hum Vaccin Immunother; 2022 Nov; 18(5):2051412. PubMed ID: 35302905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protective immunity following coronavirus vaccination and coronavirus infection.
    Dangi T; Palacio N; Sanchez S; Park M; Class J; Visvabharathy L; Ciucci T; Koralnik IJ; Richner JM; Penaloza-MacMaster P
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34623973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.